{"protocolSection":{"identificationModule":{"nctId":"NCT00600821","orgStudyIdInfo":{"id":"A4061030"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.","officialTitle":"Randomized Phase 2 Trial Of AG013736 Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2013-10","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-04"},"primaryCompletionDateStruct":{"date":"2011-04","type":"ACTUAL"},"completionDateStruct":{"date":"2012-10","type":"ACTUAL"},"studyFirstSubmitDate":"2008-01-03","studyFirstSubmitQcDate":"2008-01-13","studyFirstPostDateStruct":{"date":"2008-01-25","type":"ESTIMATED"},"resultsFirstSubmitDate":"2012-04-20","resultsFirstSubmitQcDate":"2012-04-21","resultsFirstPostDateStruct":{"date":"2012-05-22","type":"ESTIMATED"},"dispFirstSubmitDate":"2010-02-11","dispFirstSubmitQcDate":"2010-02-11","dispFirstPostDateStruct":{"date":"2010-02-15","type":"ESTIMATED"},"lastUpdateSubmitDate":"2013-10-16","lastUpdatePostDateStruct":{"date":"2013-11-08","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"To determine if the addition of AG-013736 to chemotherapy is beneficial in patients with advanced lung cancer who have not been previously treated."},"conditionsModule":{"conditions":["Non-Small-Cell Lung Carcinoma","Adenocarcinoma"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":118,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"B","type":"ACTIVE_COMPARATOR","description":"Bevacizumab will be administered in combination with carboplatin and paclitaxel.","interventionNames":["Drug: Bevacizumab","Drug: Carboplatin","Drug: Paclitaxel"]},{"label":"A","type":"EXPERIMENTAL","description":"AG-013736 will be administered in combination with carboplatin and paclitaxel.","interventionNames":["Drug: AG-013736 (axitinib)","Drug: Carboplatin","Drug: Paclitaxel"]}],"interventions":[{"type":"DRUG","name":"Bevacizumab","description":"Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.","armGroupLabels":["B"],"otherNames":["Avastin"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\\*min/ml, iv infusion, every 3 weeks.","armGroupLabels":["B"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks","armGroupLabels":["B"]},{"type":"DRUG","name":"AG-013736 (axitinib)","description":"AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-","armGroupLabels":["A"],"otherNames":["axitinib Taxol"]},{"type":"DRUG","name":"Carboplatin","description":"Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg\\*min/ml, iv infusion, every 3 weeks.","armGroupLabels":["A"]},{"type":"DRUG","name":"Paclitaxel","description":"Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks","armGroupLabels":["A"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS)","description":"Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \\[PD\\]), or from adverse event (AE) data (where the outcome was \"Death\").","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years"}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).","timeFrame":"Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)"},{"measure":"Percentage of Participants With Objective Response (OR)","description":"OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years"},{"measure":"Duration of Response (DR)","description":"Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years"},{"measure":"Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)","description":"Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.","timeFrame":"Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1"},{"measure":"European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.","timeFrame":"Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)"},{"measure":"European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score","description":"QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.","timeFrame":"Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)"},{"measure":"Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood","description":"RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.","timeFrame":"Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1"},{"measure":"Circulating Endothelial Cells (CEC) in Blood: Total CEC","description":"Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.","timeFrame":"Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1"},{"measure":"Circulating Endothelial Cells (CEC) in Blood","description":"Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.","timeFrame":"Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1"},{"measure":"Plasma Concentration of Soluble Proteins","description":"Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \\[VEGF\\], and vascular endothelial growth factor receptor-2 \\[VEGFR2\\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.","timeFrame":"Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1"}],"otherOutcomes":[{"measure":"Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype","description":"UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.","timeFrame":"Baseline (Day 1 of Cycle 1)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Advanced non squamous cell, lung cancer\n* No prior treatment for lung cancer except prior adjuvant therapy if last dose was \\>12 months prior to enrollment\n\nExclusion Criteria:\n\n* Prior therapy for advanced lung cancer\n* The need for blood-thinners\n* Coughing up blood","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Pfizer Investigational Site","city":"Baton Rouge","state":"Louisiana","zip":"70809","country":"United States","geoPoint":{"lat":30.44332,"lon":-91.18747}},{"facility":"Pfizer Investigational Site","city":"Pittsfield","state":"Massachusetts","zip":"01201","country":"United States","geoPoint":{"lat":42.45008,"lon":-73.24538}},{"facility":"Pfizer Investigational Site","city":"Columbus","state":"Mississippi","zip":"39705","country":"United States","geoPoint":{"lat":33.49567,"lon":-88.42726}},{"facility":"Pfizer Investigational Site","city":"Corinth","state":"Mississippi","zip":"38834","country":"United States","geoPoint":{"lat":34.93425,"lon":-88.52227}},{"facility":"Pfizer Investigational Site","city":"New Albany","state":"Mississippi","zip":"38652","country":"United States","geoPoint":{"lat":34.49427,"lon":-89.00784}},{"facility":"Pfizer Investigational Site","city":"Oxford","state":"Mississippi","zip":"38655","country":"United States","geoPoint":{"lat":34.3665,"lon":-89.51925}},{"facility":"Pfizer Investigational Site","city":"Southaven","state":"Mississippi","zip":"38671","country":"United States","geoPoint":{"lat":34.98898,"lon":-90.01259}},{"facility":"Pfizer Investigational Site","city":"Tupelo","state":"Mississippi","zip":"38801","country":"United States","geoPoint":{"lat":34.25807,"lon":-88.70464}},{"facility":"Pfizer Investigational Site","city":"Lincoln","state":"Nebraska","zip":"68510","country":"United States","geoPoint":{"lat":40.8,"lon":-96.66696}},{"facility":"Pfizer Investigational Site","city":"Cleveland","state":"Ohio","zip":"44109","country":"United States","geoPoint":{"lat":41.4995,"lon":-81.69541}},{"facility":"Pfizer Investigational Site","city":"Bartlett","state":"Tennessee","zip":"38133","country":"United States","geoPoint":{"lat":35.20453,"lon":-89.87398}},{"facility":"Pfizer Investigational Site","city":"Germantown","state":"Tennessee","zip":"38138","country":"United States","geoPoint":{"lat":35.08676,"lon":-89.81009}},{"facility":"Pfizer Investigational Site","city":"Memphis","state":"Tennessee","zip":"38119","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Pfizer Investigational Site","city":"Memphis","state":"Tennessee","zip":"38120","country":"United States","geoPoint":{"lat":35.14953,"lon":-90.04898}},{"facility":"Pfizer Investigational Site","city":"Dallas","state":"Texas","zip":"75230","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Pfizer Investigational Site","city":"Dallas","state":"Texas","zip":"75235","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Pfizer Investigational Site","city":"Dallas","state":"Texas","zip":"75246","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Pfizer Investigational Site","city":"Dallas","state":"Texas","zip":"75390-8590","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Pfizer Investigational Site","city":"Lubbock","state":"Texas","zip":"79410","country":"United States","geoPoint":{"lat":33.57786,"lon":-101.85517}},{"facility":"Pfizer Investigational Site","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Pfizer Investigational Site","city":"San Antonio","state":"Texas","zip":"78284","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}},{"facility":"Pfizer Investigational Site","city":"Wenatchee","state":"Washington","zip":"98801","country":"United States","geoPoint":{"lat":47.42346,"lon":-120.31035}},{"facility":"Pfizer Investigational Site","city":"Prague","zip":"180 81","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"Pfizer Investigational Site","city":"Tábor","zip":"390 03","country":"Czechia","geoPoint":{"lat":49.41441,"lon":14.6578}},{"facility":"Pfizer Investigational Site","city":"Ústí nad Labem","zip":"401 13","country":"Czechia","geoPoint":{"lat":50.6607,"lon":14.03227}},{"facility":"Pfizer Investigational Site","city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"Pfizer Investigational Site","city":"Paris","zip":"75679","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"facility":"Pfizer Investigational Site","city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"facility":"Pfizer Investigational Site","city":"Bydgoszcz","zip":"85-796","country":"Poland","geoPoint":{"lat":53.1235,"lon":18.00762}},{"facility":"Pfizer Investigational Site","city":"Gdansk","zip":"80-462","country":"Poland","geoPoint":{"lat":54.35227,"lon":18.64912}},{"facility":"Pfizer Investigational Site","city":"Gdynia","zip":"81-519","country":"Poland","geoPoint":{"lat":54.51889,"lon":18.53188}},{"facility":"Pfizer Investigational Site","city":"Torun","zip":"87 - 100","country":"Poland","geoPoint":{"lat":53.01375,"lon":18.59814}},{"facility":"Pfizer Investigational Site","city":"Warsaw","zip":"02-097","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Pfizer Investigational Site","city":"Alicante","state":"Alicante","zip":"03010","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"Pfizer Investigational Site","city":"Mataró","state":"Barcelona","zip":"08304","country":"Spain","geoPoint":{"lat":41.54211,"lon":2.4445}},{"facility":"Pfizer Investigational Site","city":"Sabadell","state":"Barcelona","zip":"08208","country":"Spain","geoPoint":{"lat":41.54329,"lon":2.10942}},{"facility":"Pfizer Investigational Site","city":"Valencia","state":"Valencia","zip":"46014","country":"Spain","geoPoint":{"lat":39.47391,"lon":-0.37966}},{"facility":"Pfizer Investigational Site","city":"Southampton","state":"Hampshire","zip":"SO16 6YD","country":"United Kingdom","geoPoint":{"lat":50.90395,"lon":-1.40428}},{"facility":"Pfizer Investigational Site","city":"Dundee","state":"Scotland","zip":"DD1 9SY","country":"United Kingdom","geoPoint":{"lat":56.46913,"lon":-2.97489}},{"facility":"Pfizer Investigational Site","city":"Leeds","state":"Yorkshire","zip":"LS9 7TF","country":"United Kingdom","geoPoint":{"lat":53.79648,"lon":-1.54785}},{"facility":"Pfizer Investigational Site","city":"Dundee","zip":"DD1 9SY","country":"United Kingdom","geoPoint":{"lat":56.46913,"lon":-2.97489}},{"facility":"Pfizer Investigational Site","city":"London","zip":"NW1 2PG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Pfizer Investigational Site","city":"London","zip":"SW3 6JJ","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Pfizer Investigational Site","city":"Surrey","zip":"SM2 5PT","country":"United Kingdom"}]},"referencesModule":{"references":[{"pmid":"24356624","type":"DERIVED","citation":"Twelves C, Chmielowska E, Havel L, Popat S, Swieboda-Sadlej A, Sawrycki P, Bycott P, Ingrosso A, Kim S, Williams JA, Chen C, Olszanski AJ, de Besi P, Schiller JH. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol. 2014 Jan;25(1):132-8. doi: 10.1093/annonc/mdt489."}],"seeAlsoLinks":[{"label":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061030&StudyName=A%20Study%20Of%20AG-013736%20%28Axitinib%29%20Or%20Bevacizumab%20%28Avastin%29%20In%20Combination%20With%20Paclitaxel%20And%20Carboplatin%20In%20Patients%20With%20Advanced%20"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 milligram (mg) tablet administered orally twice daily (BID) along with infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin area under the concentration-time curve (AUC) of 6 mg\\*minute/milliliter (mg\\*min/mL) infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"FG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kilogram (mg/kg) infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"60"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"59"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"60"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"45"},{"groupId":"FG001","numSubjects":"46"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Terminated by sponsor","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"6"}]},{"type":"Objective progression or relapse","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Randomized but not treated","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.","groups":[{"id":"BG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"BG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"118"}]}],"measures":[{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"Participants","classes":[{"title":"Less than 18 years","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}]},{"title":"18 to 44 years","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"45 to 64 years","categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"77"}]}]},{"title":"Greater than or equal to 65 years","categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"38"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"45"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"73"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS)","description":"Time in months from start of study treatment to first randomization date of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the first randomization date plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \\[PD\\]), or from adverse event (AE) data (where the outcome was \"Death\").","populationDescription":"Intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"4.1","upperLimit":"7.5"},{"groupId":"OG001","value":"6.1","lowerLimit":"4.2","upperLimit":"8.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Differences in PFS between treatment arms was analyzed by 1-sided log rank test, stratified by gender and prior adjuvant therapy.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.639","pValueComment":"One-sided log-rank test at alpha = 0.20 significance level was used.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.093","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.679","ciUpperLimit":"1.761"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"Time in months from date of randomization to date of death due to any cause. OS was calculated as (the death date minus the first randomization date plus 1) divided by 30.4. Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death).","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline, every 6 weeks until death or bimonthly after final study visit (up to 2.75 years)","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"7.5","upperLimit":"16.4"},{"groupId":"OG001","value":"13.3","lowerLimit":"10.4","upperLimit":"17.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Differences in OS between treatment arms was analyzed by 1-sided log rank test, stratified by gender and prior adjuvant therapy.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.699","pValueComment":"One-sided log-rank test at alpha = 0.20 significance level was used.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.117","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.739","ciUpperLimit":"1.689"}]},{"type":"SECONDARY","title":"Percentage of Participants With Objective Response (OR)","description":"OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response were those that persisted on repeat imaging study at least 4 weeks after initial documentation of response. CR: disappearance of all lesions (target and/or non target) and no appearance of new lesions. PR: at least 30 percent decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, without progression of non target lesions and no appearance of new lesions.","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug, or received a different drug from that to which they were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.3","lowerLimit":"18.1","upperLimit":"42.7"},{"groupId":"OG001","value":"43.3","lowerLimit":"30.6","upperLimit":"56.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"P-value was calculated using 1-sided Cochran-Mantel-Haenszel test stratified by gender and prior adjuvant therapy. Risk ratio in comparison to the Bevacizumab group was calculated assuming all other factors as constant.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9422","statisticalMethod":"Cochran-Mantel-Haenszel","paramType":"Risk Ratio (RR)","paramValue":"0.676","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.412","ciUpperLimit":"1.107"}]},{"type":"SECONDARY","title":"Duration of Response (DR)","description":"Time in months from the first documentation of objective tumor response that is subsequently confirmed to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.","populationDescription":"DR was calculated for the subgroup of participants from the ITT population, with a confirmed objective tumor response (CR or PR).","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Baseline, every 6 weeks until disease progression or initiation of subsequent anticancer therapy up to 2.75 years","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"26"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","lowerLimit":"4.2","upperLimit":"6.7"},{"groupId":"OG001","value":"7.0","lowerLimit":"4.8","upperLimit":"8.3"}]}]}]},{"type":"SECONDARY","title":"Population Pharmacokinetic (PK) Analysis for Axitinib (AG-013736)","description":"Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.","reportingStatus":"NOT_POSTED","timeFrame":"Pre-dose, 1 to 2 hours post-dose on Cycle 2 of Day 1 and Cycle 3 of Day 1"},{"type":"SECONDARY","title":"European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Score","description":"EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhoea, and financial difficulties). Most questions used 4- point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.","populationDescription":"ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. 'n' signifies those participants evaluated for this measure at specific time point for each group respectively.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Day (D) 1 of every cycle (C) then every 3 weeks until final study visit (up to 2.75 years)","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Physical functioning (PF): Baseline (n=58, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"66.29","spread":"22.04"},{"groupId":"OG001","value":"75.00","spread":"22.21"}]}]},{"title":"PF: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"67.45","spread":"23.48"},{"groupId":"OG001","value":"75.47","spread":"20.24"}]}]},{"title":"PF: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"65.78","spread":"24.40"},{"groupId":"OG001","value":"78.16","spread":"18.43"}]}]},{"title":"PF: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"67.88","spread":"20.01"},{"groupId":"OG001","value":"73.78","spread":"19.14"}]}]},{"title":"PF: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"61.18","spread":"24.09"},{"groupId":"OG001","value":"75.09","spread":"16.38"}]}]},{"title":"PF: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"65.86","spread":"19.17"},{"groupId":"OG001","value":"73.94","spread":"18.66"}]}]},{"title":"PF: C7 D1 (n=27, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"66.42","spread":"22.15"},{"groupId":"OG001","value":"74.89","spread":"18.67"}]}]},{"title":"PF: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"67.27","spread":"22.44"},{"groupId":"OG001","value":"77.14","spread":"18.98"}]}]},{"title":"PF: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"66.30","spread":"27.77"},{"groupId":"OG001","value":"74.57","spread":"19.02"}]}]},{"title":"PF: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"68.63","spread":"25.36"},{"groupId":"OG001","value":"81.33","spread":"14.92"}]}]},{"title":"PF: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"60.67","spread":"23.58"},{"groupId":"OG001","value":"78.25","spread":"16.00"}]}]},{"title":"PF: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"71.33","spread":"20.86"},{"groupId":"OG001","value":"78.43","spread":"19.65"}]}]},{"title":"PF: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"25.94"},{"groupId":"OG001","value":"79.05","spread":"21.22"}]}]},{"title":"PF: End of treatment (EOT) (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"62.96","spread":"21.11"},{"groupId":"OG001","value":"64.91","spread":"24.83"}]}]},{"title":"Role functioning: Baseline (n=58, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"60.92","spread":"31.15"},{"groupId":"OG001","value":"60.63","spread":"31.79"}]}]},{"title":"Role functioning: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"64.38","spread":"31.98"},{"groupId":"OG001","value":"65.41","spread":"29.02"}]}]},{"title":"Role functioning: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"58.15","spread":"34.01"},{"groupId":"OG001","value":"70.92","spread":"28.55"}]}]},{"title":"Role functioning: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"67.12","spread":"26.49"},{"groupId":"OG001","value":"67.36","spread":"25.02"}]}]},{"title":"Role functioning: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"57.35","spread":"29.64"},{"groupId":"OG001","value":"66.23","spread":"29.12"}]}]},{"title":"Role functioning: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"62.90","spread":"30.34"},{"groupId":"OG001","value":"67.68","spread":"29.15"}]}]},{"title":"Role functioning: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"55.36","spread":"32.41"},{"groupId":"OG001","value":"63.89","spread":"27.01"}]}]},{"title":"Role functioning: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"65.15","spread":"29.05"},{"groupId":"OG001","value":"71.43","spread":"19.70"}]}]},{"title":"Role functioning: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"63.89","spread":"37.60"},{"groupId":"OG001","value":"70.29","spread":"18.77"}]}]},{"title":"Role functioning: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"28.87"},{"groupId":"OG001","value":"70.83","spread":"20.14"}]}]},{"title":"Role functioning: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"60.00","spread":"29.41"},{"groupId":"OG001","value":"71.93","spread":"21.55"}]}]},{"title":"Role functioning: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"75.00","spread":"21.15"},{"groupId":"OG001","value":"70.59","spread":"21.67"}]}]},{"title":"Role functioning: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"62.50","spread":"33.04"},{"groupId":"OG001","value":"80.95","spread":"20.52"}]}]},{"title":"Role functioning: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"57.41","spread":"32.47"},{"groupId":"OG001","value":"57.90","spread":"31.18"}]}]},{"title":"Emotional functioning: Baseline (n=57, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"69.74","spread":"23.45"},{"groupId":"OG001","value":"63.74","spread":"27.44"}]}]},{"title":"Emotional functioning: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"78.33","spread":"21.76"},{"groupId":"OG001","value":"73.64","spread":"22.81"}]}]},{"title":"Emotional functioning: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"75.19","spread":"21.36"},{"groupId":"OG001","value":"78.76","spread":"20.69"}]}]},{"title":"Emotional functioning: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"75.75","spread":"20.17"},{"groupId":"OG001","value":"76.04","spread":"23.23"}]}]},{"title":"Emotional functioning: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"77.60","spread":"18.38"},{"groupId":"OG001","value":"78.51","spread":"21.37"}]}]},{"title":"Emotional functioning: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"78.74","spread":"18.97"},{"groupId":"OG001","value":"77.35","spread":"23.40"}]}]},{"title":"Emotional functioning: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"78.57","spread":"22.62"},{"groupId":"OG001","value":"79.45","spread":"20.50"}]}]},{"title":"Emotional functioning: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"77.65","spread":"19.14"},{"groupId":"OG001","value":"81.25","spread":"18.09"}]}]},{"title":"Emotional functioning: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"74.07","spread":"19.78"},{"groupId":"OG001","value":"78.50","spread":"23.39"}]}]},{"title":"Emotional functioning: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"77.94","spread":"18.85"},{"groupId":"OG001","value":"78.33","spread":"13.36"}]}]},{"title":"Emotional functioning: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"70.00","spread":"21.32"},{"groupId":"OG001","value":"82.46","spread":"18.61"}]}]},{"title":"Emotional functioning: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"74.17","spread":"27.90"},{"groupId":"OG001","value":"77.45","spread":"20.57"}]}]},{"title":"Emotional functioning: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"77.08","spread":"22.60"},{"groupId":"OG001","value":"83.93","spread":"14.79"}]}]},{"title":"Emotional functioning: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"68.52","spread":"26.39"},{"groupId":"OG001","value":"70.18","spread":"25.60"}]}]},{"title":"Cognitive Functioning: Baseline (n=57, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"80.12","spread":"24.28"},{"groupId":"OG001","value":"83.33","spread":"19.16"}]}]},{"title":"Cognitive Functioning: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"84.00","spread":"20.47"},{"groupId":"OG001","value":"84.28","spread":"21.29"}]}]},{"title":"Cognitive Functioning: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"85.19","spread":"22.81"},{"groupId":"OG001","value":"85.42","spread":"20.81"}]}]},{"title":"Cognitive Functioning: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"84.68","spread":"18.99"},{"groupId":"OG001","value":"82.64","spread":"20.03"}]}]},{"title":"Cognitive Functioning: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"84.37","spread":"19.83"},{"groupId":"OG001","value":"83.33","spread":"24.51"}]}]},{"title":"Cognitive Functioning: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"86.78","spread":"18.03"},{"groupId":"OG001","value":"81.25","spread":"21.06"}]}]},{"title":"Cognitive Functioning: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"79.76","spread":"19.43"},{"groupId":"OG001","value":"85.56","spread":"18.94"}]}]},{"title":"Cognitive Functioning: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"89.39","spread":"17.48"},{"groupId":"OG001","value":"88.69","spread":"17.00"}]}]},{"title":"Cognitive Functioning: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"84.26","spread":"15.63"},{"groupId":"OG001","value":"86.23","spread":"20.51"}]}]},{"title":"Cognitive Functioning: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"88.23","spread":"12.86"},{"groupId":"OG001","value":"90.00","spread":"13.68"}]}]},{"title":"Cognitive Functioning: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"82.22","spread":"18.33"},{"groupId":"OG001","value":"85.96","spread":"18.64"}]}]},{"title":"Cognitive Functioning: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"90.00","spread":"14.05"},{"groupId":"OG001","value":"87.25","spread":"20.01"}]}]},{"title":"Cognitive Functioning: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"85.42","spread":"13.91"},{"groupId":"OG001","value":"95.24","spread":"12.10"}]}]},{"title":"Cognitive Functioning: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"77.78","spread":"23.57"},{"groupId":"OG001","value":"78.95","spread":"22.82"}]}]},{"title":"Social functioning: Baseline (n=57, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"71.35","spread":"27.59"},{"groupId":"OG001","value":"65.50","spread":"32.25"}]}]},{"title":"Social functioning: C2 D1 (n=50, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"69.67","spread":"30.06"},{"groupId":"OG001","value":"75.32","spread":"25.24"}]}]},{"title":"Social functioning: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"71.11","spread":"27.62"},{"groupId":"OG001","value":"74.65","spread":"24.79"}]}]},{"title":"Social functioning: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"73.42","spread":"24.99"},{"groupId":"OG001","value":"71.53","spread":"29.77"}]}]},{"title":"Social functioning: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"65.10","spread":"26.22"},{"groupId":"OG001","value":"75.88","spread":"27.04"}]}]},{"title":"Social functioning: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"70.11","spread":"26.49"},{"groupId":"OG001","value":"71.88","spread":"26.92"}]}]},{"title":"Social functioning: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"64.88","spread":"32.50"},{"groupId":"OG001","value":"72.22","spread":"23.71"}]}]},{"title":"Social functioning: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"71.97","spread":"24.87"},{"groupId":"OG001","value":"72.02","spread":"24.45"}]}]},{"title":"Social functioning: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"74.07","spread":"29.83"},{"groupId":"OG001","value":"81.16","spread":"16.13"}]}]},{"title":"Social functioning: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"72.55","spread":"32.24"},{"groupId":"OG001","value":"79.17","spread":"20.14"}]}]},{"title":"Social functioning: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"28.17"},{"groupId":"OG001","value":"78.95","spread":"16.52"}]}]},{"title":"Social functioning: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"71.67","spread":"20.86"},{"groupId":"OG001","value":"80.39","spread":"20.61"}]}]},{"title":"Social functioning: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"56.25","spread":"28.08"},{"groupId":"OG001","value":"80.95","spread":"18.32"}]}]},{"title":"Social functioning: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"69.14","spread":"26.03"},{"groupId":"OG001","value":"65.79","spread":"26.83"}]}]},{"title":"Fatigue: Baseline (n=57, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"40.45","spread":"23.94"},{"groupId":"OG001","value":"38.89","spread":"28.02"}]}]},{"title":"Fatigue: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"43.57","spread":"21.98"},{"groupId":"OG001","value":"36.48","spread":"25.26"}]}]},{"title":"Fatigue: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"47.41","spread":"22.77"},{"groupId":"OG001","value":"33.80","spread":"19.38"}]}]},{"title":"Fatigue: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"42.34","spread":"19.22"},{"groupId":"OG001","value":"37.85","spread":"19.40"}]}]},{"title":"Fatigue: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"44.61","spread":"21.73"},{"groupId":"OG001","value":"36.84","spread":"22.83"}]}]},{"title":"Fatigue: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"45.16","spread":"23.65"},{"groupId":"OG001","value":"33.50","spread":"21.45"}]}]},{"title":"Fatigue: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"47.82","spread":"27.27"},{"groupId":"OG001","value":"40.74","spread":"21.11"}]}]},{"title":"Fatigue: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"44.95","spread":"24.84"},{"groupId":"OG001","value":"32.14","spread":"20.14"}]}]},{"title":"Fatigue: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"40.12","spread":"29.80"},{"groupId":"OG001","value":"28.98","spread":"20.03"}]}]},{"title":"Fatigue: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"41.83","spread":"25.62"},{"groupId":"OG001","value":"30.00","spread":"19.78"}]}]},{"title":"Fatigue: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"47.78","spread":"32.52"},{"groupId":"OG001","value":"28.07","spread":"14.52"}]}]},{"title":"Fatigue: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"37.78","spread":"19.74"},{"groupId":"OG001","value":"29.41","spread":"18.82"}]}]},{"title":"Fatigue: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"50.00","spread":"24.49"},{"groupId":"OG001","value":"26.19","spread":"22.05"}]}]},{"title":"Fatigue: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"51.03","spread":"24.51"},{"groupId":"OG001","value":"43.13","spread":"27.57"}]}]},{"title":"Nausea and vomiting: Baseline (n=57, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"8.77","spread":"17.85"},{"groupId":"OG001","value":"9.89","spread":"21.91"}]}]},{"title":"Nausea and vomiting: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"7.19","spread":"13.02"},{"groupId":"OG001","value":"5.35","spread":"12.56"}]}]},{"title":"Nausea and vomiting: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"17.77"},{"groupId":"OG001","value":"5.67","spread":"11.67"}]}]},{"title":"Nausea and vomiting: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"10.81","spread":"16.77"},{"groupId":"OG001","value":"7.29","spread":"11.86"}]}]},{"title":"Nausea and vomiting: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"13.24","spread":"21.63"},{"groupId":"OG001","value":"7.46","spread":"14.34"}]}]},{"title":"Nausea and vomiting: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"13.44","spread":"21.26"},{"groupId":"OG001","value":"10.61","spread":"17.59"}]}]},{"title":"Nausea and vomiting: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"15.48","spread":"22.65"},{"groupId":"OG001","value":"9.44","spread":"14.31"}]}]},{"title":"Nausea and vomiting: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"14.40","spread":"22.00"},{"groupId":"OG001","value":"5.95","spread":"12.18"}]}]},{"title":"Nausea and vomiting: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":"13.06"},{"groupId":"OG001","value":"5.07","spread":"20.98"}]}]},{"title":"Nausea and vomiting: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"11.77","spread":"15.33"},{"groupId":"OG001","value":"8.33","spread":"16.67"}]}]},{"title":"Nausea and vomiting: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"14.45","spread":"17.67"},{"groupId":"OG001","value":"5.26","spread":"9.71"}]}]},{"title":"Nausea and vomiting: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"15.00","spread":"16.57"},{"groupId":"OG001","value":"6.68","spread":"14.50"}]}]},{"title":"Nausea and vomiting: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"17.25"},{"groupId":"OG001","value":"5.95","spread":"14.03"}]}]},{"title":"Nausea and vomiting: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"16.05","spread":"22.40"},{"groupId":"OG001","value":"7.90","spread":"14.36"}]}]},{"title":"Pain: Baseline (n=57, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"31.29","spread":"31.82"},{"groupId":"OG001","value":"35.31","spread":"30.02"}]}]},{"title":"Pain: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"29.74","spread":"29.87"},{"groupId":"OG001","value":"28.30","spread":"29.16"}]}]},{"title":"Pain: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"30.00","spread":"27.43"},{"groupId":"OG001","value":"18.75","spread":"18.07"}]}]},{"title":"Pain: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"26.58","spread":"18.62"},{"groupId":"OG001","value":"25.35","spread":"27.29"}]}]},{"title":"Pain: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"18.91"},{"groupId":"OG001","value":"24.12","spread":"24.72"}]}]},{"title":"Pain: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"31.18","spread":"18.63"},{"groupId":"OG001","value":"25.25","spread":"28.90"}]}]},{"title":"Pain: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"28.57","spread":"28.99"},{"groupId":"OG001","value":"27.22","spread":"26.07"}]}]},{"title":"Pain: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"28.03","spread":"25.91"},{"groupId":"OG001","value":"22.62","spread":"23.66"}]}]},{"title":"Pain: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"22.14"},{"groupId":"OG001","value":"27.54","spread":"31.22"}]}]},{"title":"Pain: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"30.39","spread":"26.51"},{"groupId":"OG001","value":"24.17","spread":"24.47"}]}]},{"title":"Pain: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"43.33","spread":"28.03"},{"groupId":"OG001","value":"18.42","spread":"21.44"}]}]},{"title":"Pain: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"35.00","spread":"21.45"},{"groupId":"OG001","value":"23.53","spread":"29.50"}]}]},{"title":"Pain: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"35.42","spread":"24.30"},{"groupId":"OG001","value":"16.67","spread":"21.68"}]}]},{"title":"Pain: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"38.27","spread":"33.27"},{"groupId":"OG001","value":"34.65","spread":"30.36"}]}]},{"title":"Dyspnoea: Baseline (n=56, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"32.74","spread":"30.15"},{"groupId":"OG001","value":"36.21","spread":"33.21"}]}]},{"title":"Dyspnoea: C2 D1 (n=51, 52)","categories":[{"measurements":[{"groupId":"OG000","value":"32.03","spread":"28.25"},{"groupId":"OG001","value":"24.36","spread":"31.04"}]}]},{"title":"Dyspnoea: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"38.52","spread":"28.39"},{"groupId":"OG001","value":"19.15","spread":"23.82"}]}]},{"title":"Dyspnoea: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"30.43"},{"groupId":"OG001","value":"21.53","spread":"25.25"}]}]},{"title":"Dyspnoea: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"36.27","spread":"33.20"},{"groupId":"OG001","value":"23.68","spread":"27.84"}]}]},{"title":"Dyspnoea: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"36.56","spread":"31.45"},{"groupId":"OG001","value":"20.20","spread":"23.48"}]}]},{"title":"Dyspnoea: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"38.09","spread":"31.05"},{"groupId":"OG001","value":"21.11","spread":"20.50"}]}]},{"title":"Dyspnoea: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"27.27","spread":"28.43"},{"groupId":"OG001","value":"16.67","spread":"19.24"}]}]},{"title":"Dyspnoea: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"25.93","spread":"33.44"},{"groupId":"OG001","value":"21.74","spread":"21.58"}]}]},{"title":"Dyspnoea: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"27.45","spread":"31.70"},{"groupId":"OG001","value":"18.33","spread":"17.01"}]}]},{"title":"Dyspnoea: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"37.78","spread":"33.01"},{"groupId":"OG001","value":"17.54","spread":"23.22"}]}]},{"title":"Dyspnoea: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"23.33","spread":"27.44"},{"groupId":"OG001","value":"21.57","spread":"23.40"}]}]},{"title":"Dyspnoea: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"37.50","spread":"37.53"},{"groupId":"OG001","value":"19.05","spread":"17.12"}]}]},{"title":"Dyspnoea: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"35.80","spread":"27.62"},{"groupId":"OG001","value":"33.33","spread":"33.78"}]}]},{"title":"Insomnia: Baseline (n=57, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"46.20","spread":"33.19"},{"groupId":"OG001","value":"37.93","spread":"31.50"}]}]},{"title":"Insomnia: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"36.60","spread":"36.06"},{"groupId":"OG001","value":"28.30","spread":"33.59"}]}]},{"title":"Insomnia: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"30.37","spread":"33.20"},{"groupId":"OG001","value":"29.08","spread":"33.06"}]}]},{"title":"Insomnia: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"24.32","spread":"26.81"},{"groupId":"OG001","value":"27.08","spread":"28.89"}]}]},{"title":"Insomnia: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"28.43","spread":"24.80"},{"groupId":"OG001","value":"23.68","spread":"31.87"}]}]},{"title":"Insomnia: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"24.73","spread":"25.77"},{"groupId":"OG001","value":"24.24","spread":"29.19"}]}]},{"title":"Insomnia: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"23.81","spread":"28.48"},{"groupId":"OG001","value":"25.55","spread":"24.26"}]}]},{"title":"Insomnia: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"21.21","spread":"26.32"},{"groupId":"OG001","value":"19.05","spread":"23.00"}]}]},{"title":"Insomnia: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"25.93","spread":"31.43"},{"groupId":"OG001","value":"23.19","spread":"27.40"}]}]},{"title":"Insomnia: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"27.45","spread":"26.97"},{"groupId":"OG001","value":"20.00","spread":"25.13"}]}]},{"title":"Insomnia: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"28.17"},{"groupId":"OG001","value":"22.81","spread":"24.97"}]}]},{"title":"Insomnia: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"26.67","spread":"21.08"},{"groupId":"OG001","value":"23.53","spread":"28.30"}]}]},{"title":"Insomnia: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"17.25"},{"groupId":"OG001","value":"16.67","spread":"17.29"}]}]},{"title":"Insomnia: EOT (n=27, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"28.39","spread":"27.28"},{"groupId":"OG001","value":"36.94","spread":"30.21"}]}]},{"title":"Loss of appetite: Baseline (n=57, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"29.82","spread":"28.65"},{"groupId":"OG001","value":"31.64","spread":"34.14"}]}]},{"title":"Loss of appetite: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"26.91"},{"groupId":"OG001","value":"20.75","spread":"29.40"}]}]},{"title":"Loss of appetite: C3 D1 (n=44, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"32.94"},{"groupId":"OG001","value":"17.02","spread":"25.89"}]}]},{"title":"Loss of appetite: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"26.13","spread":"26.22"},{"groupId":"OG001","value":"23.61","spread":"27.47"}]}]},{"title":"Loss of appetite: C5 D1 (n=34, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"30.39","spread":"33.20"},{"groupId":"OG001","value":"21.05","spread":"29.43"}]}]},{"title":"Loss of appetite: C6 D1 (n=31, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"27.96","spread":"31.15"},{"groupId":"OG001","value":"23.23","spread":"26.98"}]}]},{"title":"Loss of appetite: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"39.29","spread":"34.01"},{"groupId":"OG001","value":"24.44","spread":"23.05"}]}]},{"title":"Loss of appetite: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"36.36","spread":"28.93"},{"groupId":"OG001","value":"19.05","spread":"21.14"}]}]},{"title":"Loss of appetite: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"31.48","spread":"26.75"},{"groupId":"OG001","value":"13.04","spread":"24.08"}]}]},{"title":"Loss of appetite: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"39.22","spread":"31.70"},{"groupId":"OG001","value":"20.00","spread":"25.13"}]}]},{"title":"Loss of appetite: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"35.64"},{"groupId":"OG001","value":"15.79","spread":"17.10"}]}]},{"title":"Loss of appetite: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"},{"groupId":"OG001","value":"23.53","spread":"30.65"}]}]},{"title":"Loss of appetite: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"29.17","spread":"21.36"},{"groupId":"OG001","value":"16.67","spread":"28.49"}]}]},{"title":"Loss of appetite: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"39.51","spread":"34.64"},{"groupId":"OG001","value":"37.72","spread":"33.93"}]}]},{"title":"Constipation: Baseline (n=56, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"15.48","spread":"23.75"},{"groupId":"OG001","value":"21.05","spread":"31.89"}]}]},{"title":"Constipation: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"21.33","spread":"28.38"},{"groupId":"OG001","value":"20.13","spread":"26.43"}]}]},{"title":"Constipation: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"18.52","spread":"24.16"},{"groupId":"OG001","value":"14.89","spread":"23.88"}]}]},{"title":"Constipation: C4 D1 (n=36, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"18.52","spread":"26.96"},{"groupId":"OG001","value":"13.19","spread":"21.46"}]}]},{"title":"Constipation: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"18.75","spread":"22.30"},{"groupId":"OG001","value":"21.05","spread":"27.31"}]}]},{"title":"Constipation: C6 D1 (n=28, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"22.62","spread":"25.75"},{"groupId":"OG001","value":"19.19","spread":"28.90"}]}]},{"title":"Constipation: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"26.64"},{"groupId":"OG001","value":"7.78","spread":"14.34"}]}]},{"title":"Constipation: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"19.70","spread":"19.68"},{"groupId":"OG001","value":"2.38","spread":"8.74"}]}]},{"title":"Constipation: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":"19.15"},{"groupId":"OG001","value":"5.80","spread":"12.92"}]}]},{"title":"Constipation: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"17.65","spread":"20.81"},{"groupId":"OG001","value":"5.00","spread":"12.21"}]}]},{"title":"Constipation: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"20.57"},{"groupId":"OG001","value":"8.77","spread":"18.73"}]}]},{"title":"Constipation: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"23.31"},{"groupId":"OG001","value":"5.88","spread":"17.62"}]}]},{"title":"Constipation: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"25.20"},{"groupId":"OG001","value":"4.76","spread":"12.10"}]}]},{"title":"Constipation: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"20.99","spread":"29.45"},{"groupId":"OG001","value":"14.03","spread":"24.05"}]}]},{"title":"Diarrhoea: Baseline (n=55, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"17.45"},{"groupId":"OG001","value":"5.85","spread":"14.26"}]}]},{"title":"Diarrhoea: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"11.33","spread":"17.31"},{"groupId":"OG001","value":"10.06","spread":"21.27"}]}]},{"title":"Diarrhoea: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"15.55","spread":"18.26"},{"groupId":"OG001","value":"9.72","spread":"21.70"}]}]},{"title":"Diarrhoea: C4 D1 (n=37, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"13.51","spread":"19.97"},{"groupId":"OG001","value":"5.67","spread":"12.66"}]}]},{"title":"Diarrhoea: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"22.92","spread":"32.17"},{"groupId":"OG001","value":"7.89","spread":"18.07"}]}]},{"title":"Diarrhoea: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"21.84","spread":"28.56"},{"groupId":"OG001","value":"10.42","spread":"19.74"}]}]},{"title":"Diarrhoea: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"26.45"},{"groupId":"OG001","value":"11.11","spread":"15.98"}]}]},{"title":"Diarrhoea: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"24.24","spread":"31.17"},{"groupId":"OG001","value":"4.76","spread":"11.88"}]}]},{"title":"Diarrhoea: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"27.78","spread":"28.58"},{"groupId":"OG001","value":"5.80","spread":"12.92"}]}]},{"title":"Diarrhoea: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"30.65"},{"groupId":"OG001","value":"10.00","spread":"19.04"}]}]},{"title":"Diarrhoea: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"31.11","spread":"34.43"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"43.33","spread":"16.10"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Diarrhoea: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"25.20"},{"groupId":"OG001","value":"7.14","spread":"14.19"}]}]},{"title":"Diarrhoea: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"23.46","spread":"28.96"},{"groupId":"OG001","value":"3.51","spread":"12.94"}]}]},{"title":"Financial difficulties: Baseline (n=56, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"22.62","spread":"31.85"},{"groupId":"OG001","value":"21.64","spread":"27.09"}]}]},{"title":"Financial difficulties: C2 D1 (n=49, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"21.77","spread":"31.59"},{"groupId":"OG001","value":"20.12","spread":"27.22"}]}]},{"title":"Financial difficulties: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"25.93","spread":"30.89"},{"groupId":"OG001","value":"18.05","spread":"23.78"}]}]},{"title":"Financial difficulties: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"21.62","spread":"27.46"},{"groupId":"OG001","value":"20.83","spread":"30.46"}]}]},{"title":"Financial difficulties: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"26.04","spread":"30.21"},{"groupId":"OG001","value":"21.05","spread":"28.39"}]}]},{"title":"Financial difficulties: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"26.44","spread":"28.70"},{"groupId":"OG001","value":"20.83","spread":"29.02"}]}]},{"title":"Financial difficulties: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"26.19","spread":"31.89"},{"groupId":"OG001","value":"26.67","spread":"30.83"}]}]},{"title":"Financial difficulties: C8 D1 (n=21, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"28.57","spread":"35.41"},{"groupId":"OG001","value":"21.43","spread":"32.98"}]}]},{"title":"Financial difficulties: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"27.78","spread":"36.60"},{"groupId":"OG001","value":"17.39","spread":"29.93"}]}]},{"title":"Financial difficulties: C10 D1 (n=17, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"27.45","spread":"33.82"},{"groupId":"OG001","value":"24.56","spread":"33.04"}]}]},{"title":"Financial difficulties: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"20.00","spread":"30.34"},{"groupId":"OG001","value":"19.30","spread":"27.92"}]}]},{"title":"Financial difficulties: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"23.31"},{"groupId":"OG001","value":"17.65","spread":"26.66"}]}]},{"title":"Financial difficulties: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"20.83","spread":"35.36"},{"groupId":"OG001","value":"16.67","spread":"28.49"}]}]},{"title":"Financial difficulties: EOT (n=27, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"23.46","spread":"27.45"},{"groupId":"OG001","value":"28.83","spread":"32.55"}]}]},{"title":"Global health status/QoL: Baseline (n=57, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"53.22","spread":"22.03"},{"groupId":"OG001","value":"54.97","spread":"21.06"}]}]},{"title":"Global health status/QoL: C2 D1 (n=49, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"58.16","spread":"20.38"},{"groupId":"OG001","value":"59.59","spread":"17.78"}]}]},{"title":"Global health status/QoL: C3 D1 (n=45, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"56.67","spread":"20.07"},{"groupId":"OG001","value":"59.72","spread":"16.34"}]}]},{"title":"Global health status/QoL: C4 D1 (n=37, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"57.21","spread":"18.02"},{"groupId":"OG001","value":"57.80","spread":"18.17"}]}]},{"title":"Global health status/QoL: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"58.07","spread":"21.94"},{"groupId":"OG001","value":"61.84","spread":"17.61"}]}]},{"title":"Global health status/QoL: C6 D1 (n=29, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"53.45","spread":"17.75"},{"groupId":"OG001","value":"60.94","spread":"17.51"}]}]},{"title":"Global health status/QoL: C7 D1 (n=28, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"55.65","spread":"20.17"},{"groupId":"OG001","value":"58.61","spread":"15.39"}]}]},{"title":"Global health status/QoL: C8 D1 (n=22, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"56.82","spread":"17.18"},{"groupId":"OG001","value":"60.71","spread":"15.36"}]}]},{"title":"Global health status/QoL: C9 D1 (n=18, 22)","categories":[{"measurements":[{"groupId":"OG000","value":"56.48","spread":"23.14"},{"groupId":"OG001","value":"64.40","spread":"15.89"}]}]},{"title":"Global health status/QoL: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"55.39","spread":"17.91"},{"groupId":"OG001","value":"62.50","spread":"14.93"}]}]},{"title":"Global health status/QoL: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"47.78","spread":"19.02"},{"groupId":"OG001","value":"63.60","spread":"15.52"}]}]},{"title":"Global health status/QoL: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"54.17","spread":"19.35"},{"groupId":"OG001","value":"63.73","spread":"12.48"}]}]},{"title":"Global health status/QoL: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"53.13","spread":"19.89"},{"groupId":"OG001","value":"58.33","spread":"15.68"}]}]},{"title":"Global health status/QoL: EOT (n=27, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"49.38","spread":"20.92"},{"groupId":"OG001","value":"50.22","spread":"21.62"}]}]}]},{"type":"SECONDARY","title":"European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Lung Cancer-13 (QLQ- LC13) Score","description":"QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer and treatment side effects typical of treatment with chemotherapy and radiotherapy. The 13 questions comprised 1 multi-item scale for dyspnoea and 10 single-item symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, and medicine for pain). Recall period: past week; response range: not at all to very much. Scale score range: 0 to 100. Higher symptom score = greater degree of symptoms.","populationDescription":"ITT population included participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or different drug from which they were randomized. 'n' signifies those participants evaluated for this measure at specific time point for each group respectively.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Units on a scale","timeFrame":"Day 1 of every cycle then every 3 weeks until final study visit (up to 2.75 years)","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"}]}],"classes":[{"title":"Cough: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"37.50","spread":"31.18"},{"groupId":"OG001","value":"38.42","spread":"24.62"}]}]},{"title":"Cough: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"30.67","spread":"24.13"},{"groupId":"OG001","value":"30.19","spread":"20.94"}]}]},{"title":"Cough: C3 D1 (n=46, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"28.98","spread":"25.92"},{"groupId":"OG001","value":"28.37","spread":"23.03"}]}]},{"title":"Cough: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"29.73","spread":"25.80"},{"groupId":"OG001","value":"27.08","spread":"20.23"}]}]},{"title":"Cough: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"18.00"},{"groupId":"OG001","value":"28.07","spread":"23.92"}]}]},{"title":"Cough: C6 D1 (n=29, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"26.44","spread":"24.20"},{"groupId":"OG001","value":"26.26","spread":"23.21"}]}]},{"title":"Cough: C7 D1 (n=28, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"21.52"},{"groupId":"OG001","value":"25.29","spread":"24.65"}]}]},{"title":"Cough: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"21.21","spread":"19.37"},{"groupId":"OG001","value":"19.75","spread":"21.20"}]}]},{"title":"Cough: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"20.37","spread":"20.26"},{"groupId":"OG001","value":"24.64","spread":"25.06"}]}]},{"title":"Cough: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"23.53","spread":"25.73"},{"groupId":"OG001","value":"21.67","spread":"22.36"}]}]},{"title":"Cough: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"24.44","spread":"23.46"},{"groupId":"OG001","value":"26.31","spread":"23.78"}]}]},{"title":"Cough: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"26.66","spread":"14.05"},{"groupId":"OG001","value":"29.41","spread":"30.92"}]}]},{"title":"Cough: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"25.20"},{"groupId":"OG001","value":"21.43","spread":"21.11"}]}]},{"title":"Cough: End of treatment (EOT) (n=26, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"21.08"},{"groupId":"OG001","value":"33.33","spread":"29.00"}]}]},{"title":"Haemoptysis: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"11.51"},{"groupId":"OG001","value":"3.39","spread":"10.16"}]}]},{"title":"Haemoptysis: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":"9.13"},{"groupId":"OG001","value":"1.89","spread":"7.78"}]}]},{"title":"Haemoptysis: C3 D1 (n=44, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"5.02"},{"groupId":"OG001","value":"5.67","spread":"14.44"}]}]},{"title":"Haemoptysis: C4 D1 (n=36, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"5.56"},{"groupId":"OG001","value":"3.47","spread":"10.29"}]}]},{"title":"Haemoptysis: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"1.01","spread":"5.80"},{"groupId":"OG001","value":"3.51","spread":"12.94"}]}]},{"title":"Haemoptysis: C6 D1 (n=29, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"3.45","spread":"13.64"},{"groupId":"OG001","value":"3.03","spread":"12.81"}]}]},{"title":"Haemoptysis: C7 D1 (n=27, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"3.45","spread":"10.33"}]}]},{"title":"Haemoptysis: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"1.23","spread":"6.41"}]}]},{"title":"Haemoptysis: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Haemoptysis: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Haemoptysis: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Haemoptysis: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Haemoptysis: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"4.17","spread":"11.78"},{"groupId":"OG001","value":"0.00","spread":"0.00"}]}]},{"title":"Haemoptysis: EOT (n=26, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"0.00","spread":"0.00"},{"groupId":"OG001","value":"5.26","spread":"16.49"}]}]},{"title":"Dyspnoea: Baseline (n=56, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"29.17","spread":"20.60"},{"groupId":"OG001","value":"31.42","spread":"28.85"}]}]},{"title":"Dyspnoea: C2 D1 (n=48, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"29.86","spread":"25.23"},{"groupId":"OG001","value":"23.90","spread":"21.51"}]}]},{"title":"Dyspnoea: C3 D1 (n=45, 43)","categories":[{"measurements":[{"groupId":"OG000","value":"33.83","spread":"22.09"},{"groupId":"OG001","value":"20.41","spread":"18.61"}]}]},{"title":"Dyspnoea: C4 D1 (n=36, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"32.10","spread":"20.01"},{"groupId":"OG001","value":"24.69","spread":"21.57"}]}]},{"title":"Dyspnoea: C5 D1 (n=33, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"30.30","spread":"21.21"},{"groupId":"OG001","value":"23.12","spread":"19.84"}]}]},{"title":"Dyspnoea: C6 D1 (n=28, 31)","categories":[{"measurements":[{"groupId":"OG000","value":"35.32","spread":"24.76"},{"groupId":"OG001","value":"21.86","spread":"18.70"}]}]},{"title":"Dyspnoea: C7 D1 (n=27, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"30.45","spread":"25.52"},{"groupId":"OG001","value":"20.16","spread":"16.02"}]}]},{"title":"Dyspnoea: C8 D1 (n=22, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"24.75","spread":"21.94"},{"groupId":"OG001","value":"21.37","spread":"16.61"}]}]},{"title":"Dyspnoea: C9 D1 (n=18, 22)","categories":[{"measurements":[{"groupId":"OG000","value":"27.78","spread":"29.83"},{"groupId":"OG001","value":"18.69","spread":"14.70"}]}]},{"title":"Dyspnoea: C10 D1 (n=17, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"28.76","spread":"27.80"},{"groupId":"OG001","value":"19.88","spread":"15.08"}]}]},{"title":"Dyspnoea: C11 D1 (n=15, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"27.41","spread":"24.80"},{"groupId":"OG001","value":"19.75","spread":"15.51"}]}]},{"title":"Dyspnoea: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"23.33","spread":"22.50"},{"groupId":"OG001","value":"22.22","spread":"19.25"}]}]},{"title":"Dyspnoea: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"37.50","spread":"31.95"},{"groupId":"OG001","value":"16.67","spread":"16.16"}]}]},{"title":"Dyspnoea: EOT (n=25, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"34.22","spread":"23.33"},{"groupId":"OG001","value":"33.63","spread":"28.39"}]}]},{"title":"Sore Mouth: Baseline (n=56, 58)","categories":[{"measurements":[{"groupId":"OG000","value":"3.57","spread":"12.19"},{"groupId":"OG001","value":"1.15","spread":"6.13"}]}]},{"title":"Sore Mouth: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"18.95","spread":"26.88"},{"groupId":"OG001","value":"9.43","spread":"23.00"}]}]},{"title":"Sore Mouth: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"18.52","spread":"28.03"},{"groupId":"OG001","value":"9.22","spread":"21.65"}]}]},{"title":"Sore Mouth: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"21.62","spread":"31.64"},{"groupId":"OG001","value":"8.33","spread":"21.19"}]}]},{"title":"Sore Mouth: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"23.23","spread":"36.79"},{"groupId":"OG001","value":"11.40","spread":"23.60"}]}]},{"title":"Sore Mouth: C6 D1 (n=28, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"30.77"},{"groupId":"OG001","value":"6.06","spread":"19.46"}]}]},{"title":"Sore Mouth: C7 D1 (n=28, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"17.86","spread":"27.94"},{"groupId":"OG001","value":"6.90","spread":"16.38"}]}]},{"title":"Sore Mouth: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"30.43"},{"groupId":"OG001","value":"3.70","spread":"10.67"}]}]},{"title":"Sore Mouth: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":"15.36"},{"groupId":"OG001","value":"5.80","spread":"16.37"}]}]},{"title":"Sore Mouth: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"19.61","spread":"33.46"},{"groupId":"OG001","value":"10.00","spread":"26.71"}]}]},{"title":"Sore Mouth: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"22.22","spread":"37.09"},{"groupId":"OG001","value":"8.77","spread":"24.45"}]}]},{"title":"Sore Mouth: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"23.57"},{"groupId":"OG001","value":"7.84","spread":"18.74"}]}]},{"title":"Sore Mouth: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"38.83"},{"groupId":"OG001","value":"4.76","spread":"12.10"}]}]},{"title":"Sore Mouth: EOT (n=26, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"8.97","spread":"24.14"},{"groupId":"OG001","value":"4.39","spread":"13.80"}]}]},{"title":"Dysphagia: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"6.55","spread":"17.31"},{"groupId":"OG001","value":"6.78","spread":"14.88"}]}]},{"title":"Dysphagia: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"11.76","spread":"22.92"},{"groupId":"OG001","value":"6.92","spread":"17.73"}]}]},{"title":"Dysphagia: C3 D1 (n=46, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"13.77","spread":"20.58"},{"groupId":"OG001","value":"4.96","spread":"11.99"}]}]},{"title":"Dysphagia: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"9.91","spread":"20.59"},{"groupId":"OG001","value":"2.78","spread":"9.31"}]}]},{"title":"Dysphagia: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"12.50","spread":"26.44"},{"groupId":"OG001","value":"4.39","spread":"11.42"}]}]},{"title":"Dysphagia: C6 D1 (n=28, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"13.10","spread":"27.73"},{"groupId":"OG001","value":"7.07","spread":"16.15"}]}]},{"title":"Dysphagia: C7 D1 (n=28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"11.90","spread":"26.00"},{"groupId":"OG001","value":"5.95","spread":"15.85"}]}]},{"title":"Dysphagia: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"26.73"},{"groupId":"OG001","value":"1.23","spread":"6.41"}]}]},{"title":"Dysphagia: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"9.26","spread":"15.36"},{"groupId":"OG001","value":"1.45","spread":"6.95"}]}]},{"title":"Dysphagia: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"21.57","spread":"26.20"},{"groupId":"OG001","value":"6.67","spread":"17.44"}]}]},{"title":"Dysphagia: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"24.44","spread":"29.46"},{"groupId":"OG001","value":"1.75","spread":"7.65"}]}]},{"title":"Dysphagia: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"6.67","spread":"14.05"},{"groupId":"OG001","value":"3.92","spread":"16.17"}]}]},{"title":"Dysphagia: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"20.83","spread":"24.80"},{"groupId":"OG001","value":"4.76","spread":"17.82"}]}]},{"title":"Dysphagia: EOT (n=26, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"7.69","spread":"21.72"},{"groupId":"OG001","value":"7.89","spread":"19.66"}]}]},{"title":"Peripheral neuropathy: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"9.52","spread":"19.81"},{"groupId":"OG001","value":"15.25","spread":"26.50"}]}]},{"title":"Peripheral neuropathy: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"24.84","spread":"30.44"},{"groupId":"OG001","value":"33.96","spread":"33.01"}]}]},{"title":"Peripheral neuropathy: C3 D1 (n=46, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"37.68","spread":"34.15"},{"groupId":"OG001","value":"34.75","spread":"36.09"}]}]},{"title":"Peripheral neuropathy: C4 D1 (n=37, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"45.05","spread":"37.86"},{"groupId":"OG001","value":"38.19","spread":"32.97"}]}]},{"title":"Peripheral neuropathy: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"50.51","spread":"39.19"},{"groupId":"OG001","value":"42.11","spread":"33.50"}]}]},{"title":"Peripheral neuropathy: C6 D1 (n=29, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"55.17","spread":"39.11"},{"groupId":"OG001","value":"52.53","spread":"33.37"}]}]},{"title":"Peripheral neuropathy: C7 D1 (n=28, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"48.81","spread":"37.93"},{"groupId":"OG001","value":"54.02","spread":"33.82"}]}]},{"title":"Peripheral neuropathy: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"57.58","spread":"40.08"},{"groupId":"OG001","value":"50.62","spread":"36.25"}]}]},{"title":"Peripheral neuropathy: C9 D1 (n=17, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"45.10","spread":"40.73"},{"groupId":"OG001","value":"56.52","spread":"36.84"}]}]},{"title":"Peripheral neuropathy: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"45.10","spread":"42.40"},{"groupId":"OG001","value":"48.33","spread":"38.20"}]}]},{"title":"Peripheral neuropathy: C11 D1 (n=14, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"50.00","spread":"42.87"},{"groupId":"OG001","value":"49.12","spread":"35.78"}]}]},{"title":"Peripheral neuropathy: C12 D1 (n=9, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"55.56","spread":"40.83"},{"groupId":"OG001","value":"54.90","spread":"38.98"}]}]},{"title":"Peripheral neuropathy: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"58.33","spread":"42.73"},{"groupId":"OG001","value":"47.62","spread":"38.60"}]}]},{"title":"Peripheral neuropathy: EOT (n=25, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"37.33","spread":"35.12"},{"groupId":"OG001","value":"40.35","spread":"38.87"}]}]},{"title":"Alopecia: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"2.98","spread":"11.51"},{"groupId":"OG001","value":"2.26","spread":"10.48"}]}]},{"title":"Alopecia: C2 D1 (n=50, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"69.33","spread":"33.56"},{"groupId":"OG001","value":"71.70","spread":"32.29"}]}]},{"title":"Alopecia: C3 D1 (n=46, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"73.91","spread":"37.13"},{"groupId":"OG001","value":"68.89","spread":"38.53"}]}]},{"title":"Alopecia: C4 D1 (n=37, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"65.77","spread":"40.43"},{"groupId":"OG001","value":"60.00","spread":"42.40"}]}]},{"title":"Alopecia: C5 D1 (n=33, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"61.62","spread":"44.19"},{"groupId":"OG001","value":"64.76","spread":"44.24"}]}]},{"title":"Alopecia: C6 D1 (n=28, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"69.05","spread":"42.48"},{"groupId":"OG001","value":"61.46","spread":"45.68"}]}]},{"title":"Alopecia: C7 D1 (n=28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"39.29","spread":"46.31"},{"groupId":"OG001","value":"40.48","spread":"45.68"}]}]},{"title":"Alopecia: C8 D1 (n=21, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"42.86","spread":"44.90"},{"groupId":"OG001","value":"44.44","spread":"48.92"}]}]},{"title":"Alopecia: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"27.78","spread":"43.16"},{"groupId":"OG001","value":"31.88","spread":"44.36"}]}]},{"title":"Alopecia: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"31.37","spread":"43.25"},{"groupId":"OG001","value":"11.67","spread":"29.17"}]}]},{"title":"Alopecia: C11 D1 (n=14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"36.40"},{"groupId":"OG001","value":"16.67","spread":"34.77"}]}]},{"title":"Alopecia: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"28.11"},{"groupId":"OG001","value":"9.80","spread":"28.30"}]}]},{"title":"Alopecia: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"8.33","spread":"23.57"},{"groupId":"OG001","value":"7.14","spread":"26.73"}]}]},{"title":"Alopecia: EOT (n=26, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"42.16"},{"groupId":"OG001","value":"27.03","spread":"39.94"}]}]},{"title":"Chest pain: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"23.81","spread":"28.93"},{"groupId":"OG001","value":"20.90","spread":"25.45"}]}]},{"title":"Chest pain: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"18.95","spread":"27.69"},{"groupId":"OG001","value":"10.06","spread":"18.00"}]}]},{"title":"Chest pain: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":"25.18"},{"groupId":"OG001","value":"5.67","spread":"12.66"}]}]},{"title":"Chest pain: C4 D1 (n=36, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":"24.49"},{"groupId":"OG001","value":"9.03","spread":"19.13"}]}]},{"title":"Chest pain: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"11.11","spread":"19.84"},{"groupId":"OG001","value":"3.51","spread":"10.37"}]}]},{"title":"Chest pain: C6 D1 (n=28, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"15.48","spread":"21.24"},{"groupId":"OG001","value":"1.01","spread":"5.80"}]}]},{"title":"Chest pain: C7 D1 (n=28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"11.90","spread":"18.62"},{"groupId":"OG001","value":"3.57","spread":"10.50"}]}]},{"title":"Chest pain: C8 D1 (n=22, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"13.64","spread":"16.77"},{"groupId":"OG001","value":"3.70","spread":"10.67"}]}]},{"title":"Chest pain: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"12.96","spread":"20.26"},{"groupId":"OG001","value":"7.25","spread":"14.06"}]}]},{"title":"Chest pain: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"13.72","spread":"16.91"},{"groupId":"OG001","value":"8.33","spread":"18.34"}]}]},{"title":"Chest pain: C11 D1 (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"24.44","spread":"29.46"},{"groupId":"OG001","value":"7.02","spread":"13.96"}]}]},{"title":"Chest pain: C12 D1 (n=10, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"13.33","spread":"17.21"},{"groupId":"OG001","value":"2.08","spread":"8.33"}]}]},{"title":"Chest pain: C13 D1 (n=7, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"19.05","spread":"26.23"},{"groupId":"OG001","value":"4.76","spread":"12.10"}]}]},{"title":"Chest pain: EOT (n=26, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"30.77","spread":"33.89"},{"groupId":"OG001","value":"15.31","spread":"24.34"}]}]},{"title":"Arm/shoulder pain: Baseline (n=56, 59)","categories":[{"measurements":[{"groupId":"OG000","value":"20.83","spread":"27.39"},{"groupId":"OG001","value":"20.34","spread":"29.04"}]}]},{"title":"Arm/shoulder pain: C2 D1 (n=51, 53)","categories":[{"measurements":[{"groupId":"OG000","value":"20.91","spread":"28.25"},{"groupId":"OG001","value":"20.75","spread":"24.66"}]}]},{"title":"Arm/shoulder pain: C3 D1 (n=45, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":"25.18"},{"groupId":"OG001","value":"5.67","spread":"12.66"}]}]},{"title":"Arm/shoulder pain: C4 D1 (n=37, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"18.92","spread":"25.51"},{"groupId":"OG001","value":"17.02","spread":"30.19"}]}]},{"title":"Arm/shoulder pain: C5 D1 (n=33, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"14.14","spread":"26.39"},{"groupId":"OG001","value":"14.91","spread":"26.51"}]}]},{"title":"Arm/shoulder pain: C6 D1 (n=29, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"16.09","spread":"26.16"},{"groupId":"OG001","value":"5.05","spread":"12.14"}]}]},{"title":"Arm/shoulder pain: C7 D1 (n=28, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"15.48","spread":"23.10"},{"groupId":"OG001","value":"14.94","spread":"22.86"}]}]},{"title":"Arm/shoulder pain: C8 D1 (n=22, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"26.73"},{"groupId":"OG001","value":"14.10","spread":"19.26"}]}]},{"title":"Arm/shoulder pain: C9 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"14.81","spread":"23.49"},{"groupId":"OG001","value":"13.04","spread":"19.43"}]}]},{"title":"Arm/shoulder pain: C10 D1 (n=17, 20)","categories":[{"measurements":[{"groupId":"OG000","value":"13.73","spread":"23.74"},{"groupId":"OG001","value":"20.00","spread":"27.36"}]}]},{"title":"Arm/shoulder pain: C11 D1 (n=14, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"26.19","spread":"29.75"},{"groupId":"OG001","value":"15.79","spread":"23.22"}]}]},{"title":"Arm/shoulder pain: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"23.33","spread":"22.50"},{"groupId":"OG001","value":"25.49","spread":"32.34"}]}]},{"title":"Arm/shoulder pain: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"20.83","spread":"24.80"},{"groupId":"OG001","value":"19.05","spread":"25.20"}]}]},{"title":"Arm/shoulder pain: EOT (n=26, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"21.80","spread":"33.92"},{"groupId":"OG001","value":"23.68","spread":"31.87"}]}]},{"title":"Other pain: Baseline (n=52, 57)","categories":[{"measurements":[{"groupId":"OG000","value":"28.85","spread":"32.36"},{"groupId":"OG001","value":"25.15","spread":"34.09"}]}]},{"title":"Other pain: C2 D1 (n=49, 50)","categories":[{"measurements":[{"groupId":"OG000","value":"26.53","spread":"28.85"},{"groupId":"OG001","value":"32.67","spread":"31.94"}]}]},{"title":"Other pain: C3 D1 (n=46, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"34.06","spread":"31.81"},{"groupId":"OG001","value":"23.40","spread":"31.79"}]}]},{"title":"Other pain: C4 D1 (n=36, 45)","categories":[{"measurements":[{"groupId":"OG000","value":"25.93","spread":"27.73"},{"groupId":"OG001","value":"28.15","spread":"30.11"}]}]},{"title":"Other pain: C5 D1 (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"29.33"},{"groupId":"OG001","value":"26.32","spread":"33.02"}]}]},{"title":"Other pain: C6 D1 (n=28, 33)","categories":[{"measurements":[{"groupId":"OG000","value":"29.76","spread":"26.20"},{"groupId":"OG001","value":"27.27","spread":"33.80"}]}]},{"title":"Other pain: C7 D1 (n=28, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"32.14","spread":"35.70"},{"groupId":"OG001","value":"35.71","spread":"36.21"}]}]},{"title":"Other pain: C8 D1 (n=22, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"16.67","spread":"28.64"},{"groupId":"OG001","value":"25.64","spread":"33.08"}]}]},{"title":"Other pain: C9 D1 (n=15, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"31.11","spread":"34.43"},{"groupId":"OG001","value":"31.88","spread":"34.05"}]}]},{"title":"Other pain: C10 D1 (n=16, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"25.00","spread":"28.55"},{"groupId":"OG001","value":"22.81","spread":"31.53"}]}]},{"title":"Other pain: C11 D1 (n=14, 18)","categories":[{"measurements":[{"groupId":"OG000","value":"42.86","spread":"33.15"},{"groupId":"OG001","value":"25.93","spread":"33.44"}]}]},{"title":"Other pain: C12 D1 (n=10, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"33.33","spread":"27.22"},{"groupId":"OG001","value":"27.45","spread":"33.82"}]}]},{"title":"Other pain: C13 D1 (n=8, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"29.17","spread":"27.82"},{"groupId":"OG001","value":"26.19","spread":"29.75"}]}]},{"title":"Other pain: EOT (n=25, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"34.67","spread":"32.60"},{"groupId":"OG001","value":"29.73","spread":"36.67"}]}]},{"title":"Medicine for pain: Baseline (n=37, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"60.36","spread":"29.23"},{"groupId":"OG001","value":"66.67","spread":"28.01"}]}]},{"title":"Medicine for pain: C3 D1 (n=29, 24)","categories":[{"measurements":[{"groupId":"OG000","value":"65.52","spread":"31.48"},{"groupId":"OG001","value":"68.06","spread":"31.82"}]}]},{"title":"Medicine for pain: C4 D1 (n=19, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"63.16","spread":"26.98"},{"groupId":"OG001","value":"72.41","spread":"23.69"}]}]},{"title":"Medicine for pain: C5 D1 (n=17, 22)","categories":[{"measurements":[{"groupId":"OG000","value":"70.59","spread":"26.04"},{"groupId":"OG001","value":"72.73","spread":"22.15"}]}]},{"title":"Medicine for pain: C6 D1 (n=16, 17)","categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"29.81"},{"groupId":"OG001","value":"72.55","spread":"24.25"}]}]},{"title":"Medicine for pain: C7 D1 (n=15, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"75.56","spread":"26.63"},{"groupId":"OG001","value":"66.67","spread":"29.24"}]}]},{"title":"Medicine for pain: C8 D1 (n=13, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"66.67","spread":"27.22"},{"groupId":"OG001","value":"75.00","spread":"25.82"}]}]},{"title":"Medicine for pain: C9 D1 (n=6, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"72.23","spread":"13.61"},{"groupId":"OG001","value":"69.05","spread":"20.52"}]}]},{"title":"Medicine for pain: C10 D1 (n=10, 10)","categories":[{"measurements":[{"groupId":"OG000","value":"73.34","spread":"14.05"},{"groupId":"OG001","value":"60.00","spread":"26.30"}]}]},{"title":"Medicine for pain: C11 D1 (n=9, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"48.15","spread":"17.57"},{"groupId":"OG001","value":"81.48","spread":"17.57"}]}]},{"title":"Medicine for pain: C12 D1 (n=6, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"55.56","spread":"17.22"},{"groupId":"OG001","value":"70.37","spread":"20.03"}]}]},{"title":"Medicine for pain: C13 D1 (n=0, 0)","categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA","comment":"Data was not analyzed as no participants were evaluable for the particular cycle."},{"groupId":"OG001","value":"NA","spread":"NA","comment":"Data was not analyzed as no participants were evaluable for the particular cycle."}]}]},{"title":"Medicine for pain: EOT (n=15, 19)","categories":[{"measurements":[{"groupId":"OG000","value":"60.00","spread":"22.54"},{"groupId":"OG001","value":"66.67","spread":"29.40"}]}]},{"title":"Medicine for pain: C2 D1 (n=30, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"62.22","spread":"22.72"},{"groupId":"OG001","value":"71.43","spread":"26.99"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants by Ribonucleic Acid (RNA) Expression Profile in Whole Blood","description":"RNA expression profiles of genes which were associated with tumor growth, angiogenesis and metastases were collected and correlated with efficacy.","populationDescription":"Data was not generated but sample was collected for banking and moved to a separate exploratory research database for future research.","reportingStatus":"POSTED","timeFrame":"Baseline, C1 D1, C1 D15, C2 D1, C3 D1, C4 D1 and C5 D1","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"type":"SECONDARY","title":"Circulating Endothelial Cells (CEC) in Blood: Total CEC","description":"Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.","populationDescription":"ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. 'n': participants evaluated at specific time point for each group respectively. 'N' (Number of participants analyzed) signifies participants evaluable for the measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Cells/milliliter (cells/mL)","timeFrame":"Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Baseline (n=39, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"46815.38","spread":"131531.755"},{"groupId":"OG001","value":"16960.41","spread":"25527.526"}]}]},{"title":"C1 D15 (n=27, 29)","categories":[{"measurements":[{"groupId":"OG000","value":"11780.15","spread":"13127.847"},{"groupId":"OG001","value":"21882.41","spread":"67578.781"}]}]},{"title":"C2 D1 (n=32, 28)","categories":[{"measurements":[{"groupId":"OG000","value":"29229.09","spread":"55724.997"},{"groupId":"OG001","value":"40507.36","spread":"82161.060"}]}]},{"title":"C3 D1 (n=24, 30)","categories":[{"measurements":[{"groupId":"OG000","value":"19517.50","spread":"19793.722"},{"groupId":"OG001","value":"25215.70","spread":"42932.747"}]}]},{"title":"C4 D1 (n=20, 27)","categories":[{"measurements":[{"groupId":"OG000","value":"24556.05","spread":"22434.011"},{"groupId":"OG001","value":"41944.59","spread":"70239.938"}]}]},{"title":"C5 D1 (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"28266.22","spread":"39480.209"},{"groupId":"OG001","value":"37468.13","spread":"82647.380"}]}]},{"title":"C7 D1 (n=11, 14)","categories":[{"measurements":[{"groupId":"OG000","value":"71770.91","spread":"94182.032"},{"groupId":"OG001","value":"36964.36","spread":"60577.084"}]}]},{"title":"C9 D1 (n=7, 7)","categories":[{"measurements":[{"groupId":"OG000","value":"58680.00","spread":"78138.794"},{"groupId":"OG001","value":"107978.14","spread":"206314.489"}]}]},{"title":"C11 D1 (n=6, 6)","categories":[{"measurements":[{"groupId":"OG000","value":"116620.83","spread":"129577.280"},{"groupId":"OG001","value":"120847.67","spread":"140674.394"}]}]}]},{"type":"SECONDARY","title":"Circulating Endothelial Cells (CEC) in Blood","description":"Circulating endothelial cells (CECs) are noninvasive marker of vascular damage, remodeling, and dysfunction. Total CEC, plasma-vascular endothelial growth factor receptor-2 (pVEGFR2), VEGFR2, p-Beta-type platelet-derived growth factor receptor (pPDGFRB+) and PDGFRB+ were explored using CECs. Blood was collected to analyze effects of therapy on the number, viability/apoptotic state, and/or target activity/expression in CECs.","populationDescription":"ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. 'n': participants evaluated at specific time point for each group respectively. 'N' (Number of participants analyzed) signifies participants evaluable for the measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Flourescent Intensity Unit (FIU)","timeFrame":"Baseline (C1 D1), C1 D15, C2 D1, C3 D1, C4 D1, C5 D1, C7 D1, C9 D1 and C11 D1","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"59"}]}],"classes":[{"title":"Baseline (pVEGFR2+) (n=50, 42)","categories":[{"measurements":[{"groupId":"OG000","value":"1936317.98","spread":"1252665.900"},{"groupId":"OG001","value":"1764577.67","spread":"1331540.549"}]}]},{"title":"C1 D15 (pVEGFR2+) (n=38, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"1822095.74","spread":"1678888.153"},{"groupId":"OG001","value":"1810049.32","spread":"1330590.809"}]}]},{"title":"C2 D1 (pVEGFR2+) (n=41, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"1767065.44","spread":"1442193.213"},{"groupId":"OG001","value":"2090673.60","spread":"1659128.892"}]}]},{"title":"C3 D1 (pVEGFR2+) (n=33, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"1715569.39","spread":"1515661.662"},{"groupId":"OG001","value":"1578940.53","spread":"1274415.109"}]}]},{"title":"C4 D1 (pVEGFR2+) (n=25, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"1472447.68","spread":"970463.341"},{"groupId":"OG001","value":"1815402.16","spread":"1263516.725"}]}]},{"title":"C5 D1 (pVEGFR2+) (n=24, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"2208801.96","spread":"3098289.400"},{"groupId":"OG001","value":"1794843.58","spread":"1458412.725"}]}]},{"title":"C7 D1 (pVEGFR2+) (n=16, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"1405048.00","spread":"879770.893"},{"groupId":"OG001","value":"1634128.00","spread":"1443612.089"}]}]},{"title":"C9 D1 (pVEGFR2+) (n=12, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"2280989.75","spread":"1050678.808"},{"groupId":"OG001","value":"2283985.00","spread":"1093158.760"}]}]},{"title":"C11 D1 (pVEGFR2+) (n=10, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"1828224.90","spread":"1179020.490"},{"groupId":"OG001","value":"2354939.11","spread":"1116283.011"}]}]},{"title":"Baseline (VEGFR2+) (n=50, 42)","categories":[{"measurements":[{"groupId":"OG000","value":"1694522.56","spread":"1534520.504"},{"groupId":"OG001","value":"1841618.36","spread":"1300088.201"}]}]},{"title":"C1 D15 (VEGFR2+) (n=38, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"1634956.89","spread":"1285333.248"},{"groupId":"OG001","value":"1740268.05","spread":"1444881.394"}]}]},{"title":"C2 D1 (VEGFR2+) (n=41, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"1597041.59","spread":"865675.123"},{"groupId":"OG001","value":"1444404.94","spread":"1097875.465"}]}]},{"title":"C3 D1 (VEGFR2+) (n=33, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"1443986.61","spread":"843071.909"},{"groupId":"OG001","value":"1504595.71","spread":"1163469.112"}]}]},{"title":"C4 D1 (VEGFR2+) (n=25, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"1181666.88","spread":"673860.407"},{"groupId":"OG001","value":"1259913.44","spread":"765707.741"}]}]},{"title":"C5 D1 (VEGFR2+) (n=24, 25)","categories":[{"measurements":[{"groupId":"OG000","value":"1371956.00","spread":"948166.942"},{"groupId":"OG001","value":"1447188.88","spread":"885864.695"}]}]},{"title":"C7 D1 (VEGFR2+) (n=16, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"1028231.44","spread":"495059.378"},{"groupId":"OG001","value":"1317560.13","spread":"720095.027"}]}]},{"title":"C9 D1 (VEGFR2+) (n=12, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"1485819.58","spread":"953884.288"},{"groupId":"OG001","value":"1476621.00","spread":"1688887.819"}]}]},{"title":"C11 D1 (VEGFR2+) (n=10, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"1573298.80","spread":"1152155.993"},{"groupId":"OG001","value":"1332064.78","spread":"668964.428"}]}]},{"title":"Baseline (pPDGFRB+) (n=50, 42)","categories":[{"measurements":[{"groupId":"OG000","value":"1646702.34","spread":"1482336.244"},{"groupId":"OG001","value":"1734853.24","spread":"1485338.326"}]}]},{"title":"C1 D15 (pPDGFRB+) (n=38, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"1253893.97","spread":"894629.298"},{"groupId":"OG001","value":"1599671.65","spread":"1669690.889"}]}]},{"title":"C2 D1 (pPDGFRB+) (n=41, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"1395311.88","spread":"1111766.454"},{"groupId":"OG001","value":"1885684.31","spread":"1356916.305"}]}]},{"title":"C3 D1 (pPDGFRB+) (n=33, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"1470448.94","spread":"841336.398"},{"groupId":"OG001","value":"1285439.44","spread":"1083860.541"}]}]},{"title":"C4 D1 (pPDGFRB+) (n=25, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"1046445.72","spread":"588769.375"},{"groupId":"OG001","value":"1514713.97","spread":"1150805.007"}]}]},{"title":"C5 D1 (pPDGFRB+) (n=24, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"2253114.67","spread":"3314986.569"},{"groupId":"OG001","value":"2299459.38","spread":"5140939.706"}]}]},{"title":"C7 D1 (pPDGFRB+) (n=16, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"1380133.19","spread":"1002147.826"},{"groupId":"OG001","value":"2163313.88","spread":"3720352.717"}]}]},{"title":"C9 D1 (pPDGFRB+) (n=12, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"2172539.75","spread":"2323386.087"},{"groupId":"OG001","value":"2225289.18","spread":"1126401.528"}]}]},{"title":"C11 D1 (pPDGFRB+) (n=10, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"1580028.90","spread":"927582.364"},{"groupId":"OG001","value":"3127640.22","spread":"2817719.865"}]}]},{"title":"Baseline (PDGFRB+) (n=50, 42)","categories":[{"measurements":[{"groupId":"OG000","value":"1775826.12","spread":"1485762.540"},{"groupId":"OG001","value":"3176459.69","spread":"3222201.986"}]}]},{"title":"C1 D15 (PDGFRB+) (n=38, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"1589914.37","spread":"985828.939"},{"groupId":"OG001","value":"1819988.05","spread":"1807664.991"}]}]},{"title":"C2 D1 (PDGFRB+) (n=41, 35)","categories":[{"measurements":[{"groupId":"OG000","value":"1840677.73","spread":"1315688.806"},{"groupId":"OG001","value":"1586256.17","spread":"1092406.544"}]}]},{"title":"C3 D1 (PDGFRB+) (n=33, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"1690163.33","spread":"1064816.034"},{"groupId":"OG001","value":"1518360.71","spread":"1286285.813"}]}]},{"title":"C4 D1 (PDGFRB+) (n=25, 32)","categories":[{"measurements":[{"groupId":"OG000","value":"1288624.64","spread":"641546.254"},{"groupId":"OG001","value":"1408366.91","spread":"1013859.813"}]}]},{"title":"C5 D1 (PDGFRB+) (n=24, 26)","categories":[{"measurements":[{"groupId":"OG000","value":"1309639.50","spread":"975890.557"},{"groupId":"OG001","value":"1364500.50","spread":"1058758.211"}]}]},{"title":"C7 D1 (PDGFRB+) (n=16, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"1049351.00","spread":"587546.139"},{"groupId":"OG001","value":"1287039.25","spread":"922009.811"}]}]},{"title":"C9 D1 (PDGFRB+) (n=12, 11)","categories":[{"measurements":[{"groupId":"OG000","value":"1666413.67","spread":"1465165.325"},{"groupId":"OG001","value":"1625161.64","spread":"1467355.491"}]}]},{"title":"C11 D1 (PDGFRB+) (n=10, 9)","categories":[{"measurements":[{"groupId":"OG000","value":"1533606.00","spread":"1258733.501"},{"groupId":"OG001","value":"1959067.11","spread":"1973194.943"}]}]}]},{"type":"SECONDARY","title":"Plasma Concentration of Soluble Proteins","description":"Plasma concentrations of soluble proteins (soluble- stem-cell factor receptor (sKIT) vascular endothelial growth factor \\[VEGF\\], and vascular endothelial growth factor receptor-2 \\[VEGFR2\\], VEGFR3) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.","populationDescription":"ITT population: participants randomized with study drug designated according to initial randomization, regardless of whether participants received study drug or different drug. 'n': participants evaluated at specific time point for each group respectively. 'N' (Number of participants analyzed) signifies participants evaluable for the measure.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Picogram/mL (pg/mL)","timeFrame":"Baseline, C1D1, C1D15, C2D1, C3D1, C4D1, C5D1, C7D1, C9D1 and C11D1","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"58"}]}],"classes":[{"title":"Baseline (SKIT) (n=52, 47)","categories":[{"measurements":[{"groupId":"OG000","value":"49740.29","spread":"16998.69"},{"groupId":"OG001","value":"49544.15","spread":"14803.62"}]}]},{"title":"C1 D15 (SKIT) (n=42, 36)","categories":[{"measurements":[{"groupId":"OG000","value":"53095.48","spread":"18233.85"},{"groupId":"OG001","value":"55801.39","spread":"22058.63"}]}]},{"title":"C2 D1 (SKIT) (n=41, 43)","categories":[{"measurements":[{"groupId":"OG000","value":"52979.39","spread":"18018.73"},{"groupId":"OG001","value":"55729.65","spread":"21476.66"}]}]},{"title":"C3 D1 (SKIT) (n=40, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"53817.75","spread":"19638.72"},{"groupId":"OG001","value":"65634.14","spread":"27097.91"}]}]},{"title":"C4 D1 (SKIT) (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"56961.41","spread":"20828.07"},{"groupId":"OG001","value":"72671.32","spread":"33207.22"}]}]},{"title":"C5 D1 (SKIT) (n=27, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"58305.00","spread":"20311.85"},{"groupId":"OG001","value":"68677.21","spread":"30073.83"}]}]},{"title":"C7 D1 (SKIT) (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"50701.11","spread":"17927.98"},{"groupId":"OG001","value":"75547.61","spread":"24458.54"}]}]},{"title":"C9 D1 (SKIT) (n=12, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"48680.42","spread":"14791.32"},{"groupId":"OG001","value":"65990.78","spread":"17003.08"}]}]},{"title":"C11 D1 (SKIT) (n=11, 13)","categories":[{"measurements":[{"groupId":"OG000","value":"49251.82","spread":"19469.45"},{"groupId":"OG001","value":"66920.38","spread":"12261.25"}]}]},{"title":"Baseline (VEGF) (n=50, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"95.14","spread":"66.60"},{"groupId":"OG001","value":"121.83","spread":"141.22"}]}]},{"title":"C1 D15 (VEGF) (n=40, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"117.08","spread":"98.05"},{"groupId":"OG001","value":"287.19","spread":"171.77"}]}]},{"title":"C2 D1 (VEGF) (n=39, 43)","categories":[{"measurements":[{"groupId":"OG000","value":"127.46","spread":"128.06"},{"groupId":"OG001","value":"324.33","spread":"153.65"}]}]},{"title":"C3 D1 (VEGF) (n=39, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"148.06","spread":"159.80"},{"groupId":"OG001","value":"368.23","spread":"151.20"}]}]},{"title":"C4 D1 (VEGF) (n=30, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"197.16","spread":"282.49"},{"groupId":"OG001","value":"405.13","spread":"173.86"}]}]},{"title":"C5 D1 (VEGF) (n=25, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"184.77","spread":"175.32"},{"groupId":"OG001","value":"400.16","spread":"165.69"}]}]},{"title":"C7 D1 (VEGF) (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"226.62","spread":"202.53"},{"groupId":"OG001","value":"433.30","spread":"172.14"}]}]},{"title":"C9 D1 (VEGF) (n=12, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"273.17","spread":"207.22"},{"groupId":"OG001","value":"422.38","spread":"157.76"}]}]},{"title":"C11 D1 (VEGF) (n=11, 13)","categories":[{"measurements":[{"groupId":"OG000","value":"339.86","spread":"303.71"},{"groupId":"OG001","value":"449.92","spread":"144.50"}]}]},{"title":"Baseline (VEGFR2) (n=52, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"9587.31","spread":"1570.27"},{"groupId":"OG001","value":"9995.00","spread":"2185.61"}]}]},{"title":"C1 D15 (VEGFR2) (n=42, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"7828.10","spread":"1959.39"},{"groupId":"OG001","value":"10781.35","spread":"2311.90"}]}]},{"title":"C2 D1 (VEGFR2) (n=41, 43)","categories":[{"measurements":[{"groupId":"OG000","value":"7477.80","spread":"2146.89"},{"groupId":"OG001","value":"10330.00","spread":"2511.23"}]}]},{"title":"C3 D1 (VEGFR2) (n=40, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"7058.50","spread":"2037.12"},{"groupId":"OG001","value":"10129.47","spread":"2244.65"}]}]},{"title":"C4 D1 (VEGFR2) (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"6885.94","spread":"1754.19"},{"groupId":"OG001","value":"9934.21","spread":"1785.78"}]}]},{"title":"C5 D1 (VEGFR2) (n=27, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"6565.93","spread":"1755.75"},{"groupId":"OG001","value":"10140.59","spread":"2056.40"}]}]},{"title":"C7 D1 (VEGFR2) (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"6401.11","spread":"2360.24"},{"groupId":"OG001","value":"10339.57","spread":"1897.95"}]}]},{"title":"C9 D1 (VEGFR2) (n=12, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"6291.67","spread":"2235.24"},{"groupId":"OG001","value":"9421.25","spread":"2446.42"}]}]},{"title":"C11 D1 (VEGFR2) (n=11, 13)","categories":[{"measurements":[{"groupId":"OG000","value":"5696.36","spread":"2724.57"},{"groupId":"OG001","value":"9222.31","spread":"2727.04"}]}]},{"title":"Baseline (VEGFR3) (n=52, 48)","categories":[{"measurements":[{"groupId":"OG000","value":"44390.77","spread":"75118.17"},{"groupId":"OG001","value":"24718.33","spread":"12494.07"}]}]},{"title":"C1 D15 (VEGFR3) (n=42, 37)","categories":[{"measurements":[{"groupId":"OG000","value":"33684.29","spread":"52617.02"},{"groupId":"OG001","value":"17693.51","spread":"9679.53"}]}]},{"title":"C2 D1 (VEGFR3) (n=41, 43)","categories":[{"measurements":[{"groupId":"OG000","value":"35780.49","spread":"68287.68"},{"groupId":"OG001","value":"17798.37","spread":"9710.23"}]}]},{"title":"C3 D1 (VEGFR3) (n=40, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"34147.00","spread":"74220.30"},{"groupId":"OG001","value":"15901.32","spread":"8062.41"}]}]},{"title":"C4 D1 (VEGFR3) (n=32, 38)","categories":[{"measurements":[{"groupId":"OG000","value":"19730.94","spread":"9237.69"},{"groupId":"OG001","value":"16307.37","spread":"7409.61"}]}]},{"title":"C5 D1 (VEGFR3) (n=27, 34)","categories":[{"measurements":[{"groupId":"OG000","value":"17452.59","spread":"8614.99"},{"groupId":"OG001","value":"16381.47","spread":"6707.41"}]}]},{"title":"C7 D1 (VEGFR3) (n=18, 23)","categories":[{"measurements":[{"groupId":"OG000","value":"17896.67","spread":"8360.82"},{"groupId":"OG001","value":"15626.30","spread":"8873.31"}]}]},{"title":"C9 D1 (VEGFR3) (n=12, 16)","categories":[{"measurements":[{"groupId":"OG000","value":"21449.17","spread":"12806.75"},{"groupId":"OG001","value":"14733.44","spread":"6441.61"}]}]},{"title":"C11 D1 (VEGFR3) (n=11, 13)","categories":[{"measurements":[{"groupId":"OG000","value":"22332.73","spread":"12408.37"},{"groupId":"OG001","value":"16048.46","spread":"7064.47"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Plasma Concentration Change in the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) Genotype","description":"UGT1A1 an enzyme of the glucuronidation pathway that transforms small lipophilic molecules, such as steroids, bilirubin, hormones, and drugs, into water-soluble, excretable metabolites.","populationDescription":"Data was reported in listings but not summarized due to statistical constraints.","reportingStatus":"POSTED","timeFrame":"Baseline (Day 1 of Cycle 1)","groups":[{"id":"OG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive Axitinib (AG-013736) BID maintenance therapy."},{"id":"OG001","title":"Bevacizumab+ Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive Axitinib (AG-013736) BID maintenance therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","description":"The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.","eventGroups":[{"id":"EG000","title":"Axitinib + Paclitaxel + Carboplatin","description":"Axitinib (AG-013736) 5 mg tablet administered orally BID along with IV infusion of paclitaxel 200 mg per square meter (mg/m\\^2) over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive axitinib (AG-013736) BID maintenance therapy.","seriousNumAffected":31,"seriousNumAtRisk":58,"otherNumAffected":54,"otherNumAtRisk":58},{"id":"EG001","title":"Bevacizumab + Paclitaxel + Carboplatin","description":"Bevacizumab 15 mg/kg infusion over 90 minutes every 3 weeks along with infusion of paclitaxel 200 mg/m\\^2 over 3 hours and carboplatin AUC of 6 mg\\*min/mL infusion over 30 minutes in cycles of 3 weeks. After completion or discontinuation of treatment for reasons other than disease progression, participants continued to receive bevacizumab maintenance therapy every 3 weeks.","seriousNumAffected":19,"seriousNumAtRisk":59,"otherNumAffected":58,"otherNumAtRisk":59}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Inappropriate antidiuretic hormone secretion","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Anal fissure","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Oesophagitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Disease progression","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Anaphylactic reaction","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Endocarditis bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Loss of consciousness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Meningeal disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Hallucination","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Febrile infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":58},{"groupId":"EG001","numAffected":15,"numAtRisk":59}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":58},{"groupId":"EG001","numAffected":5,"numAtRisk":59}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":18,"numAtRisk":58},{"groupId":"EG001","numAffected":15,"numAtRisk":59}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":58},{"groupId":"EG001","numAffected":11,"numAtRisk":59}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":58},{"groupId":"EG001","numAffected":17,"numAtRisk":59}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":27,"numAtRisk":58},{"groupId":"EG001","numAffected":20,"numAtRisk":59}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":58},{"groupId":"EG001","numAffected":19,"numAtRisk":59}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":14,"numAtRisk":58},{"groupId":"EG001","numAffected":11,"numAtRisk":59}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":20,"numAtRisk":58},{"groupId":"EG001","numAffected":22,"numAtRisk":59}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":9,"numAtRisk":59}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":58},{"groupId":"EG001","numAffected":12,"numAtRisk":59}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":58},{"groupId":"EG001","numAffected":11,"numAtRisk":59}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":58},{"groupId":"EG001","numAffected":5,"numAtRisk":59}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":58},{"groupId":"EG001","numAffected":7,"numAtRisk":59}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":58},{"groupId":"EG001","numAffected":7,"numAtRisk":59}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":10,"numAtRisk":59}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":5,"numAtRisk":59}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":58},{"groupId":"EG001","numAffected":15,"numAtRisk":59}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":8,"numAtRisk":59}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":2,"numAtRisk":59}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":58},{"groupId":"EG001","numAffected":0,"numAtRisk":59}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":58},{"groupId":"EG001","numAffected":8,"numAtRisk":59}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":58},{"groupId":"EG001","numAffected":9,"numAtRisk":59}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":58},{"groupId":"EG001","numAffected":8,"numAtRisk":59}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":58},{"groupId":"EG001","numAffected":15,"numAtRisk":59}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":58},{"groupId":"EG001","numAffected":10,"numAtRisk":59}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":58},{"groupId":"EG001","numAffected":27,"numAtRisk":59}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":58},{"groupId":"EG001","numAffected":25,"numAtRisk":59}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":58},{"groupId":"EG001","numAffected":1,"numAtRisk":59}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":6,"numAtRisk":59}]},{"term":"Hyperbilirubinaemia","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":4,"numAtRisk":59}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":5,"numAtRisk":59}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]},{"term":"Rash pruritic","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA v15.1","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":58},{"groupId":"EG001","numAffected":3,"numAtRisk":59}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."},"pointOfContact":{"title":"Pfizer ClinicalTrials.gov Call Center","organization":"Pfizer, Inc.","email":"ClinicalTrials.gov_Inquiries@pfizer.com","phone":"1-800-718-1021"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"D000230","term":"Adenocarcinoma"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"},{"id":"D002277","term":"Carcinoma"},{"id":"D009375","term":"Neoplasms, Glandular and Epithelial"},{"id":"D009370","term":"Neoplasms by Histologic Type"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D016190","term":"Carboplatin"},{"id":"D017239","term":"Paclitaxel"},{"id":"D000077784","term":"Axitinib"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D001549","term":"Benzamides"},{"id":"D000577","term":"Amides"},{"id":"D001565","term":"Benzoates"},{"id":"D000146","term":"Acids, Carbocyclic"},{"id":"D002264","term":"Carboxylic Acids"},{"id":"D001555","term":"Benzene Derivatives"},{"id":"D006841","term":"Hydrocarbons, Aromatic"},{"id":"D007191","term":"Indazoles"},{"id":"D011720","term":"Pyrazoles"},{"id":"D001393","term":"Azoles"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"}]}},"hasResults":true}